(Q52854537)

8 May 2018

title

Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. (English)

1 reference

8 May 2018

0 references

1 reference

E Hensor

3

0 references

author name string

O Lily

1

1 reference

8 May 2018

E McFadden

2

1 reference

8 May 2018

M Johnson

4

1 reference

8 May 2018

H Ford

5

1 reference

8 May 2018

publication date

1 December 2006

1 reference

8 May 2018

Multiple Sclerosis Journal

published in

1 reference

8 May 2018

volume

12

1 reference

8 May 2018

issue

6

1 reference

8 May 2018

page(s)

808-813

1 reference

8 May 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Inflammation and degeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Clinical scoring methods for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Disability profile of MS did not change over 10 years in a population-based prevalence cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Quality of life and impairment in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Assessing quality of life in people with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Design and analysis of trials with quality of life as an outcome: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070946

21 January 2018

Identifiers

DOI

10.1177/1352458506070946

1 reference

8 May 2018

1 reference

8 May 2018